EURORDIS Black Pearl Awards
On 13 February 2019
At : Brussels, Belgium
On 13 February 2019
At : Brussels, Belgium
From 14 to 15 February 2019
At : Brussels, Belgium
On 21 February 2019
At : New York, USA
On 01 March 2019
At : Worldwide
From 26 to 29 March 2019
At : Bordeaux, France
From 07 to 09 November 2019
At : Madrid, Spain
From 20 to 24 January 2020
At : London, UK
A Genomics eLearning Module developed by Garvan’s Kinghorn Centre for Clinical Genomics (KCCG) in partnership with the Royal Australasian College of Physicians (RACP) has been launched as a means to introduce physicians in Australia and New Zealand to clinical genomics. This free online resource gives access to case studies, quizzes, tools and video interviews of physicians in this area of expertise.
It can be accessed for free after registration here.
From 27 February to 01 March 2019
Venue : Berlin, Germany
From 12 to 16 March 2019
At : Imagine Institute, Paris, France
Applications are now open. Applicants will be notified of the outcome of their application by mid October.
Topic: Research projects to accelerate diagnosis and/or explore disease progression and mechanisms of rare diseases
Transnational research proposals must cover at least one of the following areas, which are equal in relevance for this call:
Research to accelerate diagnosis, e.g:
Research to explore disease progression and mechanisms, e.g:
The deadline for submitting the pre-proposals is February 15, 2019.
Please check all information on the website: ejprarediseases.org
The NIH has released a notice of intent for publishing a funding opportunity for rare disease cohorts in heart, lung, blood and sleep disorders. The National Heart, Lung and Blood Institute wishes to establish cohorts in rare heart, lung, blood, and/or sleep (HLBS) diseases to allow natural history and mechanistic studies that provide the evidence base for future clinical trials and improved diagnostics.
Estimated Synopsis Post Date: December 1, 2018
Estimated Application Due Date: February 1, 2019
Applications are invited for studies the histiocytic disorders including Histiocytic Lymphohistiocytosis (HLH), Langerhans Cell Histiocytosis, or rare histiocytic disorders for a maximum budget of £50,000 and duration of up to 24 months.
Histio UK will consider scientific and clinical research on the epidemiology, pathogenesis, diagnosis, treatment and clinical care of patients with histiocytosis.
Applicants will be required to describe the likely impact of their research upon patients with histiocytosis and to outline a plan to attract further independent funding, using the award to drive forward new competitively-funded research relevant to histiocytosis. The credibility of these sections of the application will be central to a successful outcome through the review process.
The scientific review board will meet to discuss applications in May and submit their recommendations to the Trustees for approval soon after.
Eligible costs include salaries and consumables for researchers directly engaged in the proposed study but will not include PI salary, overheads, IT equipment or travel.
Closing date for applications of 5pm GMT 18 February 2019.
![]()
Please send your CV and cover letter to with the reference US14-2018-16 to:
![]()
Please send your CV and cover letter to with the reference US14 to:
![]()
Please send your CV and cover letter to with the reference US14-2018-14 to: